Description
Hemlibra 30mg Injection is a groundbreaking medication used for the treatment of hemophilia A, a genetic bleeding disorder. Its active ingredient is emicizumab, a bispecific monoclonal antibody. Unlike traditional factor replacement therapies, emicizumab works by mimicking the function of a missing clotting factor (Factor VIII) in the blood. It bridges activated Factor IX and Factor X, thereby facilitating the conversion of prothrombin to thrombin and promoting effective blood clot formation. This mechanism helps to prevent or reduce the frequency of bleeding episodes in individuals with hemophilia A, regardless of whether they have developed inhibitors to Factor VIII. Hemlibra is administered subcutaneously and is typically used for routine prophylaxis (preventive treatment). The dosage and frequency of administration are determined by a healthcare professional based on individual patient needs and response. Common side effects may include injection site reactions, headache, and joint pain. It is crucial to store Hemlibra as directed by the manufacturer, typically at room temperature and protected from light.
